Long-term ranibizumab beneficial for macular edema

October 11, 2012
Long-term ranibizumab beneficial for macular edema
Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness and improved best-corrected visual acuity, according to research published online Oct. 8 in the Archives of Ophthalmology.

(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according to research published online Oct. 8 in the Archives of Ophthalmology.

Diana V. Do, M.D., of the Wilmer Eye Institute at the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a follow-up of outcomes from the for Edema of the Macula in Diabetes study from year two (month 24) to year three (month 36) to assess the benefit of increased follow-up. Participants included 28 patients who received ranibizumab (0.5 mg monthly if FTH was 250 µm or greater), 22 patients who received laser treatment, and 24 patients who received ranibizumab plus laser treatment.

The researchers found that ranibizumab-treated patients displayed a significant mean BCVA improvement of 10.3 letters at month 36 compared with only 7.2 letters at month 24. Mean FTH was reduced from 352 to 282 µm at months 36 and 24, respectively. No statistically significant difference was observed for BCVA and FTH between the ranibizumab-plus-laser group and the laser-only group. However, ranibizumab-treated patients required significantly more injections than laser-treated patients (5.4 versus 2.3 injections), but not significantly more than the ranibizumab-plus-laser group.

"Long-term visual outcomes for treatment of with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Study suggests treatments for 'wet' AMD keep elderly drivers behind the wheel

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study suggests treatments for 'wet' AMD keep elderly drivers behind the wheel

October 2, 2012
The advanced neovascular, or "wet," form of age-related macular degeneration (AMD), left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges. But ...

Study reports two-year outcomes of diabetic macular edema treatment

April 9, 2012
A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that ...

Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration

June 13, 2011
A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white ...

Mayo Clinic detective work shows possible side effect in macular degeneration drug

October 24, 2011
Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure ...

Recommended for you

Coming soon: Glaucoma self-care, from home?

September 23, 2017
(HealthDay)—For many glaucoma patients, repeat trips to a doctor's office to check on their eyes can be a real pain.

Researchers identify potential biomarkers of age-related macular degeneration

September 12, 2017
Patients with any stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be found through special laboratory tests, according to a new study led by AMD researchers based at Massachusetts ...

Researchers unlock regenerative potential of cells in the mouse retina

August 28, 2017
Cells within an injured mouse eye can be coaxed into regenerating neurons and those new neurons appear to integrate themselves into the eye's circuitry, new research shows. The findings potentially open the door to new treatments ...

Antioxidant supplement cost saving and effective for degenerative eye disease

August 24, 2017
A supplement that combines antioxidants with zinc and copper is a relatively inexpensive and effective means of halting the progression of a certain type of degenerative eye disease, concludes research published online in ...

Researchers identify key compounds to resolve abnormal vascular growth in AMD

August 21, 2017
A compound of specific bioactive products from a major family of enzymes reduced the severity of age-related macular degeneration (AMD) in a preclinical model, according to a new study led by Massachusetts Eye and Ear researchers. ...

World's blind population to soar: study

August 3, 2017
The world's blind will increase threefold from about 36 million today to 115 million in 2050 as populations expand and individuals grow ever older, researchers said Thursday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.